| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/24/2008 | US20080020964 Test System for the Discovery of Substances for the Promotion of Neuraxonal Growth |
| 01/24/2008 | US20080020459 Progenitor cell populations, expansion thereof, and growth of non-hematopoietic cell types and tissues therefrom |
| 01/24/2008 | US20080020406 Antibodies to a human Kchannel and therapeutic applications thereof |
| 01/24/2008 | US20080020050 Medicinal delivery system, and related methods |
| 01/24/2008 | US20080020028 Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent |
| 01/24/2008 | US20080020021 5-Hydroxysapogenin derivatives with anti-dementia activity |
| 01/24/2008 | US20080020018 Combination Products |
| 01/24/2008 | US20080019986 Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof |
| 01/24/2008 | US20080019982 Administration of an activated form of ultra-low doses of antibodies to an antigen, obtained using homeopathic techniques; drug dependence/drug withdrawal; side effect reduction |
| 01/24/2008 | US20080019975 Novel Regimens for Treating Diseases and Disorders |
| 01/24/2008 | US20080019967 Inflammatory mediator antagonists |
| 01/24/2008 | US20080019964 Use of certain drugs for treating nerve root injury |
| 01/24/2008 | US20080019915 including cystic fibrosis transmembrane conductance regulator ("CFTR"); N[6-(2-hydroxymethylphenyl-1yl)-5-methylpyrimidine][(4-methoxophenyl-1-yl)cyclopopyl]-amide; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema and hemochromatosis, coagulation-fibrinolysis |
| 01/24/2008 | DE102007032613A1 Spiraprilhydrochlorid und polymorphe Formen davon Spirapril hydrochloride and polymorphic forms thereof |
| 01/24/2008 | DE102007032612A1 Polymorphe Formen von Flupirtinmaleat Polymorphic forms of flupirtine maleate |
| 01/24/2008 | DE102006034320A1 Antioxidant, useful for preparation of e.g. coloring agent, vesicle, dermocosmetic, pharmaceuticals and nutrient- or feedstuff, comprises at least an isorenieratene compound |
| 01/24/2008 | DE10121982B4 Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung Nanoparticles of protein with coupled apolipoprotein E to cross the blood-brain barrier and method for their preparation |
| 01/24/2008 | CA2693992A1 Methods of improving the pharmacokinetics of doxepin |
| 01/24/2008 | CA2671200A1 Hydrophilic abuse deterrent delivery system |
| 01/24/2008 | CA2671197A1 Hydrophobic abuse deterrent delivery system |
| 01/24/2008 | CA2659754A1 Combination of modafinil and an antagonist or inverse agonist of the h3 receptor |
| 01/24/2008 | CA2659662A1 Concentrated methotrexate solutions |
| 01/24/2008 | CA2659524A1 Novel chromene and thiochromene carboxamide derivatives, methods for preparing same and therapeutic applications of same |
| 01/24/2008 | CA2659521A1 Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders |
| 01/24/2008 | CA2659032A1 Method for inhibiting or treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates |
| 01/24/2008 | CA2658633A1 Chiral compounds substituted with phosphonic acid ester functions or phosphonic acid functions |
| 01/24/2008 | CA2658573A1 Cgrp receptor antagonists |
| 01/24/2008 | CA2658404A1 Selective antagonists of a2a adenosine receptors |
| 01/24/2008 | CA2658379A1 Spirocyclic azaindole derivatives |
| 01/24/2008 | CA2657681A1 Humanized antibodies against beta amyloid protein |
| 01/24/2008 | CA2657640A1 Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine |
| 01/24/2008 | CA2657481A1 Methods and therapies for potentiating a therapeutic action of an alpha- 2 adrenergic receptor agonist and inhibiting and/or reversing tolerance to alpha- 2 adrenergic receptor agonists |
| 01/24/2008 | CA2657280A1 Macrocyclic compounds useful as bace inhibitors |
| 01/24/2008 | CA2657269A1 New indications for direct thrombin inhibitors |
| 01/24/2008 | CA2656869A1 Macrocyclic lactams |
| 01/23/2008 | EP1880994A1 Crystal of indole derivative having piperidine ring and process for production thereof |
| 01/23/2008 | EP1880730A1 Functions and uses of gpr39 gene in mammalian central nervous system |
| 01/23/2008 | EP1880728A1 Peptide having anti-anxiety effect and method for screening thereof |
| 01/23/2008 | EP1880725A1 Liquid formulation comprising clozapine, quetiapine, a salt of quetiapine and/or olanzapine for oral administration |
| 01/23/2008 | EP1880724A1 Liquid formulation comprising clozapine, quetiapine, a salt of quetiapine and/or olanzapine for oral administration |
| 01/23/2008 | EP1880714A1 Amorphous Aripiprazole and Process for the Preparation thereof |
| 01/23/2008 | EP1879896A1 Imidazopyridazine compounds |
| 01/23/2008 | EP1879881A2 Inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
| 01/23/2008 | EP1879880A2 Dihydroxyphenylalanine derivatives |
| 01/23/2008 | EP1879875A1 Crystal forms opf {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride |
| 01/23/2008 | EP1879874A2 Process for preparing quetiapine and quetiapine fumarate |
| 01/23/2008 | EP1879865A1 Syntheses and preparations of polymorphs of crystalline aripiprazole |
| 01/23/2008 | EP1879860A2 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia |
| 01/23/2008 | EP1879856A2 Alkyl-, alkenyl- and alkynyl carbamate derivatives, the preparation and therapeutic use thereof |
| 01/23/2008 | EP1879855A2 Trpv1 agonist compounds and methods for making and using the same |
| 01/23/2008 | EP1879854A1 Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid |
| 01/23/2008 | EP1879853A1 Pregabalin free of isobutylglutaric acid and a process for preparation thereof |
| 01/23/2008 | EP1879852A1 Pregabalin free of lactam and a process for preparation thereof |
| 01/23/2008 | EP1879619A2 Analgesic combination of sodium channel blockers with opioid antagonists |
| 01/23/2008 | EP1879613A2 Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease |
| 01/23/2008 | EP1879592A1 Use of inhibitors of steroid (testosterone) activity (i.a. estrogens) or antiandrogens) for treatment of substance correlated disorders like drug abuse |
| 01/23/2008 | EP1879591A1 Use of azapaullones for preventing and treating pancreatic autoimmune disorders |
| 01/23/2008 | EP1879590A1 Eslicarbazepine acetate and methods of use |
| 01/23/2008 | EP1879574A2 Multimediator 5-ht6 receptor antagonists, and uses related thereto |
| 01/23/2008 | EP1879569A2 Therapeutic combinations for the treatment or prevention of psychotic disorders |
| 01/23/2008 | EP1879567A1 Amino acid derivatives |
| 01/23/2008 | EP1879562A2 Phenol derivatives and their use to modulate pkb activity |
| 01/23/2008 | EP1644339B1 6-arylamino-5-cyano-4-pyrimidinones as pde9a inhibitors |
| 01/23/2008 | EP1572679A4 Crfr1 selective ligands |
| 01/23/2008 | EP1556354B1 Therapeutic piperazine derivates useful for treating pain |
| 01/23/2008 | EP1532144B1 quinuclidine derivatives and their use |
| 01/23/2008 | EP1501801B1 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases |
| 01/23/2008 | EP1490366B1 alkoxypyridine-derivatives |
| 01/23/2008 | EP1330451B1 Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide y modulators |
| 01/23/2008 | EP1272514B1 Dna encoding human vanilloid receptor vr3 |
| 01/23/2008 | EP1268425B1 Carbamate caspase inhibitors and uses thereof |
| 01/23/2008 | EP1257547B1 1,3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists |
| 01/23/2008 | EP1257281B8 Nucleoside analogs with carboxamidine modified monocyclic base |
| 01/23/2008 | EP1237880B1 Pyrazine based inhibitors of glycogen synthase kinase 3 |
| 01/23/2008 | EP1216032B1 Oral controlled release formulations |
| 01/23/2008 | EP1196404B1 Piperazine derivatives as modulators of chemokine receptor activity |
| 01/23/2008 | EP1137406B2 Transdermal patch for delivering volatile liquid drugs |
| 01/23/2008 | CN101111494A Therapeutic pyrazolo[3,4-b]pyridines and indazoles |
| 01/23/2008 | CN101111489A Amino-pyridines as inhibitors of beta-secretase |
| 01/23/2008 | CN101111477A Benzoyl-tetrahydropyridine as glyt-1 inhibitors |
| 01/23/2008 | CN101111472A Tetralin and indane derivatives and uses thereof |
| 01/23/2008 | CN101111243A Classes of compounds that interact with integrins |
| 01/23/2008 | CN101111237A Methods for improving drug disposition |
| 01/23/2008 | CN101108878A Glp-1 analogues |
| 01/23/2008 | CN101108236A Hemiparalysis restoration pill and method of preparing the same |
| 01/23/2008 | CN101108212A Pharmaceutical composition for treating paralysis |
| 01/23/2008 | CN101108211A Medicament for treating hemiplegia and method of preparing the same |
| 01/23/2008 | CN101107998A Health-care food improving memorization and method of preparing the same |
| 01/23/2008 | CN101107995A Traditional Chinese medicine health care beverage bag |
| 01/23/2008 | CN100363382C Endomorphin analog and its preparing method |
| 01/23/2008 | CN100363377C N heterocyclic substituted adenosine derivatives |
| 01/23/2008 | CN100363368C Thiadiazine derivatives and use thereof as positive ampa receptor modulators |
| 01/23/2008 | CN100363363C Novel quinuclidine derivatives and medicinal compositions containing the same |
| 01/23/2008 | CN100363024C Chinese traditional medicine named numb pain resolvent for treating diabetes peripheral nervous lesion |
| 01/23/2008 | CN100363011C Gastrodin slow release preparation |
| 01/23/2008 | CN100363007C Slow release preparation containing larmotriazine |
| 01/23/2008 | CN100363006C Drug addiction-stopping formulation and preparation thereof |
| 01/23/2008 | CN100363005C Composite preparation for treatment of dementia |
| 01/23/2008 | CN100363003C Sustained releasing tablet of buspirone hydrochloride |
| 01/23/2008 | CN100363002C Application of tetrandrine and Fangchinoline in preparation of medicine for improving sleep and health products |